<DOC>
	<DOCNO>NCT00958477</DOCNO>
	<brief_summary>This study intend test experimental new drug call , EMD 525797 ( Study Drug ) . This drug yet approve sale test small number people date ( prior study start another research study carry involve 37 healthy volunteer receive Study Drug ) . Until know Study Drug , use research study . This research study plan answer important question Study Drug tolerate may work patient prostate cancer bone metastases . This small study expect include 24 patient , conduct approximately 3 hospital Germany 1 hospital Brussels , Belgium . The study last last patient last study visit expect 18 month total .</brief_summary>
	<brief_title>A Study Determine Safety , Tolerability , Pharmacokinetics Dynamic Effects Different Doses Study Drug EMD 525797 Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>1 . Provision sign write informed consent 2 . Age superior equal 18 year 3 . Subjects histological cytologically proven prostate cancer evidence bone metastases bone scan CT / MRI prior chemotherapy e.g . taxane mitoxantrone Patients undergone bilateral orchiectomy continuous androgen deprivation therapy gonadotropin release hormone agonist antagonist stop antiandrogen therapy least 4 week inclusion study . Patients either stable ( i.e. , since least 3 month ) ongoing therapy bisphosphonate without bisphosphonate therapy . Initiation bisphosphonate therapy within time period prior study study allow . Total serum testosterone le 50 ng/dL 1.7 nmol/L . 4 . Evidence progressive disease , define least two PSA value individual nadir level increase least 10 % determine minimum interval 2 week screen examination . Presence measurable lesion require study entry . Nodal ( lymph node superior equal 2cm ) visceral progression sufficient trial entry independent PSA . 5 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 study entry estimate life expectancy least 3 month . 6 . Adequate hematological function , define white blood cell count ( WBC ) great equal 3 x 109/L absolute neutrophil count ( ANC ) great equal 1.5 x 109/L , lymphocyte count great equal 0.5 x 109/L ; platelet count great equal 100 x 109/L ; hemoglobin great equal 9 g/dL . 7 . Adequate hepatic function define total bilirubin level less equal 1.5 time upper limit normal ( ULN ) , aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) level less equal 2.5 x ULN ; , subject document metastatic disease liver , AST ALT level less equal 5 x ULN . 8 . Adequate renal function define serum creatinine le 1.5 mg/dL . 9 . Effective contraception . If risk conception exists , pregnancy avoid study ( SCR EOS ) well least 3 month last dosing use effective contraception method ( e.g . double barrier method ) 1 . Any systemic cytotoxic cancer treatment within 4 week treatment EMD 525797 . 2 . Acute pathologic fracture , spinal cord progression , hypercalcemia ( within 4 week period prior screen ) . 3 . Radiotherapy bone lesion , orthopaedic surgery , investigational drug 30 day start treatment study treatment period , and/or biopsy involve bone within 2 week start treatment study . 4 . Supraphysiologic dos steroid ( define superior equal 7.5 mg prednisone equivalent per day ) . 5 . Previous treatment antiintegrin therapy . 6 . Confirmed clinically suspect brain metastasis . 7 . Known hypersensitivity reaction component study medication . 8 . History allergic reaction monoclonal antibody ( mAb ) therapy . 9 . Uncontrolled hypertension ( systolic great equal 160 mmHg , diastolic great equal 100 mmHg ) . 10 . Current history chronic daily aspirin therapy ( ASS dose inferior equal 100 mg permit ) , bleed disorder and/or history thromboembolic event ( history superficial thrombophlebitis exclusion criterion ) ; thrombolytic oral parenteral anticoagulant within 10 day prior study start treatment period . 11 . Severe peripheral vascular disease ulceration . 12 . Unstable angina pectoris , myocardial infarction within 6 month start study treatment , clinical significant abnormal ECG screen 13 . Known alcohol drug abuse . 14 . Participation another clinical trial within past 30 day start study treatment . 15 . Dementia , alter mental status , psychiatric condition would prohibit understanding rendering informed consent . 16 . Ongoing uncontrolled infection , include active chronic hepatitis B C , ongoing HIV infection . 17 . Legal incapacity limit legal capacity . 18 . All significant disease , opinion Investigator , might impair subject 's tolerance study treatment .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Safety</keyword>
	<keyword>tolerability</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>pharmacodynamics EMD 525797</keyword>
	<keyword>prostate cancer patient</keyword>
</DOC>